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 Abstract
Background. Primary serous peritoneal psammocarcinoma (PSPP) is a rare variant of serous carcinoma characte-
rized by massive psammoma body formation and low-grade cytological features. Patients with serous psammocar-
cinoma have a protracted clinical course and relatively favourable prognosis, although a more aggressive course 
of PSPP may occur.
Case presentation: A 52-year-old woman  suffering from abdominal pain with ascites and serum CA-125 level 
substantially elevated underwent an exploratory laparoscopy which  revealed bulk disease. The pathology report 
detected PPSP at the FIGO stage IIIC. The patient received neoadjuvant chemotherapy (3 courses of paclitaxel / 
pegylated liposomal doxorubicin / carboplatin). Optimal interval debulking surgery was performed as the next step, 
followed by three courses of adjuvant chemotherapy (paclitaxel / carboplatin). Due to the fact that the patient had 
residual disease, at the second-look surgery she received consolidation therapy with intraperitoneal and intrave-
nous chemotherapy carboplatin. Eight months after the completion of treatment the patient developed disease re-
currence in the peritoneum. Palliative surgery (enterostomy) was performed. Furthermore, the patient received two 
lines of chemotherapy consisting of cyclophosphamide / cisplatin and then gemcitabine.  After twenty five months 
she developed brain metastases, treated with palliative radiotherapy. The patient died twenty eight months since 
her primary presentation of PSPP. 
Conclusion: PSPP is an infrequent variant of epithelial cancer with favourable prognosis. The disease may, however, 
take a more aggressive course. Thus, an aggressive therapy is required to postpone the progression. 
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Background 
	 Serous	psammocarcinoma	of	the	peritoneum	is	a	rare	variant	
of	epithelial	cancer.	Histologically,	PPSP	is	characterized	by	[1]	
massive	psammoma	body	 formation	 (75%),	 invasion	of	 perito-
neum	or	intraperitoneal	viscera,	moderate	cytological	atypia	and	
mimic	serous	adenocarcinoma	of	 the	ovary.	Twenty-three	cases	
of	PPSP	have	been	reported	in	literature	[1-13].	Due	to	the	rarity	
and	variable	histological	criteria,	there	is	no	established	tumour	
marker	for	peritoneal	serous	psammocarcinoma.	
	 In	 the	 following	 report	we	present	 a	 case	of	 a	 patient	 suf-
fering	from	this	 rare	variant	of	cancer,	confirmed	histologically	
and	immunohistochemically.	Despite	aggressive	therapy,	the	pa-
tient	had	short	survival	time.	
Case presentation
	 A	 52-year-old	 woman	 presented	 with	 abdominal	 pain	 and	
distension.	She	was	admitted	 to	our	Institute	due	 to	ascites	and	
serum	CA-125	levels	elevated	to	the	value	of	749	U/ml.	The	com-
puted	abdominal	tomography	revealed	a	small	cyst	(26x23	mm)	
in	the	left	ovary,	a	large	omental	tumour	and	ascites.	Conseque-
ntly,	the	patient	underwent	explorative	laparoscopy	with	oopho-
rectomy	and	omentum	biopsies.	Intraoperatory	findings	showed	
large	tumour	mass	involving	the	gastrocolic	omentum	and	dense	
small	bowel	adhesions	to	pancreas	and	spleen.	Both	ovaries	were	
normal.	
	 Only	a	small	23	x	24	mm	simple	cyst	was	found	during	histo-
logical	examination	in	the	left	ovary.	The	right	ovary	was	normal.	
In	 the	 peritoneum,	 minimally	 invasive	 serous	 carcinoma	 cells	
with	moderate	cytological	atypia,	(Figure	1)	and	massive	extensi-
ve	psammoma	bodies,	(Figure	2)	were	detected.	
	 Histopathological	diagnosis	revealed	primary	serous	perito-
neal	psammocarcinoma	at	the	FIGO	stage	IIIC.	No	estrogen	and	
progesterone	receptor	was	detected	immunohistochemically.		
	 Primary	serous	peritoneal	psammocarcinoma	cells	had	CK7-
positive,	CK19-positive	and	CK20-negative	immunohistochemi-
cal	phenotype.	
	 The	patient	received	3	cycles	of	neoadjuvant	chemotherapy	
consisting	of:	paclitaxel	(175mg/m2	in	a	3-hour	infusion)	/	car-
boplatin	 (AUC	5)	 /	pegylated	 liposomal	doxorubicin	 (20mgm2)	
every	21	days,	in	accordance	with	phase	II	of	the	prospective	pilot	
study	 that	 is	 implemented	 in	 our	 institute,	 described	 elsewhere	
[14].	After	 three	 courses	 of	 such	 chemotherapy	 partial	 respon-
se	(according	 to	RECIST	criteria)	was	achieved.	Optimal	 inter-
val	 debulking	 surgery	 (≤1cm	 residual	 disease)	 was	 performed.	
Technically,	 the	 surgery	consisted	of	 total	hysterectomy,	bilate-
ral	 salpingo-oophorectomy,	 omentectomy,	 splenectomy,	 partial	
pancreas	 resection,	 appendectomy,	paraaortic	 and	pelvic	 lymph	
node	dissections	and	debulking.	The	continuation	of	the	therapy	
involved	three	courses	of	adjuvant	chemotherapy	based	on	pacli-
taxel	(175mg/m2)	/	carboplatin	(AUC6).	Minimal	residual	disease	
in	the	pathologic	examination	was	found	during	the	second-look	
operation.	At	that	time,	the	level	of	CA125	in	the	serum	was	nor-
mal.	Due	 to	 aggressive	 nature	 of	 the	 neoplasm,	 intraperitoneal	
chemotherapy	with	carboplatin	was	administered	with	an	installed	
port.	After	two	courses	of	chemotherapy	the	patient	was	urgently	
admitted	to	the	hospital	with	high	fever	(39.0°C).	Apart	from	high	
fever,	no	significant	abnormalities	were	found	during	clinical	exa-
mination.	The	CMV	infection	was	confirmed	by	positive	CMV-
IgM	in	serum.	The	patient	was	therefore	treated	with	gancyclovir	
(325mg	i.v.	b.i.d.	for	two	weeks).	Subsequent	abdominal	CT	scan	
revealed	an	enlarged	paraaortic	lymph	node.	To	determine	the	na-
ture	of	this	node,	PET	scan	was	performed.	Paraaortic	lymph	node	
enlargement	and	an	additional	lesion	confined	to	the	liver	were	fo-
und.	Therefore,	the	patient	obtained	three	cycles	of	consolidating	
systemic	chemotherapy,	consisting	of	carboplatin.	At	that	time	the	
serum	level	of	CA	125	was	normal.	
 Streszczenie
Pierwotny surowiczy piaszczakorak otrzewnej (PSPSP) jest rzadką odmianą raka surowiczego, charakteryzujący 
się obecnością licznych ciałek piaszczakowatych oraz niską złośliwością histologiczną. Chore mają względnie ko-
rzystne rokowanie, chociaż zdarza się przebieg bardziej agresywny tak jak w prezentowanej pracy.   
Opis przypadku: Chora lat 52 uskarżająca się na bóle brzucha, z cechami wodobrzusza w badaniach obrazo-
wych i znacznie podwyższonym markerem CA 125 została poddana zwiadowczej laparoskopii. Podczas operacji 
stwierdzono zaawansowaną chorobę nowotworową w jamie brzusznej przy niezmienionych przydatkach. W bada-
niu histopatologicznym rozpoznano PPSP. W zestawieniu z danymi klinicznymi zaawansowanie określono na IIIC 
wg klasyfikacji FIGO. 
Chorą zakwalifikowano do neoadjuwantowej chemioterapii (3 kursy Paklitaksel/ Pegylowana Liposomalna Doxoru-
bicyna/ Karboplatyna) a następnie poddano odroczonej optymalnej operacji cytoredukcyjnej, po której zastosowa-
no 3 cykle adjuwantowej chemioterapii (Paklitaksel/ Karboplatyna). 
W związku z obecnością minimalnej choroby resztkowej stwierdzonej w trakcie operacji drugiego wglądu, zakwalifi-
kowano pacjentkę do monoterapii karboplatyna (3 cykle) podawaną dootrzewnowo i dożylnie. Po ośmiu miesiącach 
od zakończenia chemioterapii  stwierdzono nawrót choroby nowotworowej w otrzewnej. Z powodu niedrożności 
przewodu pokarmowego przeprowadzono paliatywną operację z wyłonieniem stomii na jelicie grubym. 
Po zabiegu pacjentka otrzymała dwie linie chemioterapii według schematu Cyklofosfamid/ Cisplatyna, następnie 
monoterapię Gemcytabiną. Po 25 miesiącach od rozpoznania PSPP chorą poddano paliatywnej radioterapii z po-
wodu zmian przerzutowych do mózgu. Pacjentka zmarła  28 miesięcy po zdiagnozowaniu PSPP. 
PSPP jest rzadkim podtypem nowotworów nabłonkowych o względnie korzystnym rokowaniu. Choroba ta może 
mieć jednak agresywny przebieg  tak, jak opisano w tej pracy i chorzy ci mogą wymagać intensyfikacji leczenia. 
 Słowa kluczowe: pierwotny surowiczy piaszczakorak otrzewnej / 
      / ciałka piaszczakowate / odroczona operacja cytoredukcyjna / 
       / terapia neoadjuwantowa / 
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	 Seven	months	after	 the	 last	cycle	of	 the	consolidating	che-
motherapy,	increasing	CA	125	levels	were	observed	(from	46U/
ml	to	116U/ml).	The	control	CT	scan	revealed	stable	enlarged	pa-
raaortic	 lymph	node	 (largest	 diameter	 of	 23mm).	Another	PET	
scan	revealed	lesions	within	the	peritoneum	and	in	the	paraaortic	
lymph	nodes.	In	the	seventeenth	month	of	the	PPSP	course,	bo-
wel	obstruction	occurred.	Enterostomy	as	palliative	surgery	was	
performed.	Subsequently,	the	patient	received	four	courses	of	sal-
vage	chemotherapy	consisting	of	cyclophosphamide	(750mg/m2)	
and	cisplatin	 (75mg/m2).	She	achieved	stable	disease	according	
to	 the	RECIST	criteria	 and	CA	125	 level	with	 subsequent	pro-
gression	seen	after	further	four	months.	Therefore,	she	received	
two	courses	of	salvage	therapy	with	gemcitabine	(1250mg/m2)	on	
1st,	8th	and	15th	day	during	a	28-day	cycle.	In	the	course	of	this	
treatment	unresectable	brain	metastases	with	clinical	presentation	
appeared.	The	patient	was	 irradiated	with	 the	dose	of	2000cGy	
for	the	whole	brain.	The	patient	died	of	disease	progression,	28	
months	after	the	PPSP	was	diagnosed.	
Discussion
	 PSPP	is	a	very	rare	variant	of	peritoneal	cancer.	The	case	hi-
story	presented	above	indicates	this	malignant	disease	with	good	
prognosis	 may	 indeed	 have	 an	 aggressive	 course.	 The	 patient	
obtained	 a	 very	 aggressive,	 cytotoxic	 treatment:	 neoadjuvant,	
adjuvant,	consolidating	and	salvage	chemotherapy.	Due	to	recur-
rences,	she	received	two	lines	of	chemotherapy	with	salvage	gem-
citabine	regimens.	During	the	therapy	a	CMV	infection	occurred	
and	it	required	medication	with	gancyclovir.	The	patient	survived	
twenty	eight	months	after	the	diagnosis	of	PSPP.	
	 Both	the	epithelium	of	the	ovary	and	the	mesothelium	of	the	
peritoneum	have	the	same	embryonic	origin.	Mesenchymal	cells	
are	able	 to	give	rise	 to	epithelial	organs	 through	mesenchymal-
epithelial	 transition	that	 is	crucial	for	 the	development	of	a	pri-
mary	carcinoma.	[15]	It	 is	histologically	 indistinguishable	from	
primary	epithelial	ovarian	carcinoma,	and	its	diagnosis	requires	
differential	diagnosis	between	mesothelioma	and	ovarian	cancer.	
Immunohistochemistry	is	useful	in	distinguishing	ovarian	cancer	
from	peritoneal	mesothelioma	[16].	
	 Primary	ovarian	cancer	can	be	excluded	by	the	following	cri-
teria:	(1)	both	ovaries	must	be	of	normal	size;	(2)	the	extraovarian	
involvement	must	be	greater	than	the	involvement	on	the	surface	
of	the	ovary;	(3)	the	ovarian	component	must	be	less	than	5x5	mm	
within	the	ovary	or	confined	to	the	ovarian	surface;	and	(4)	the	
cytological	characteristics	must	be	of	the	serous	type	[17].	
	 Psammoma	 bodies	 are	 microscopic,	 laminated,	 calcinated,	
calcified	and	extracellular	bodies.	The	mechanism	of	psammocar-
cinoma	body	formation	remains	unclear	and	it	has	been	suggested	
that	psammoma	bodies	arise	as	products	of	neoplastic	and	histio-
cytic	cellular	degradation.	
	 Gilks	et	al.	[1]	proposed	some	morphological	criteria	for	the	
diagnosis	 of	 peritoneal	 psammocarcinoma	 when	 the	 following	
microscopic	features	were	present:	destructive	 invasion	of	peri-
toneal	viscera	in	extraovarian	cases;	no	more	than	moderate	cyto-
logical	atypia;	no	areas	of	solid	epithelial	proliferation	except	for	
occasional	nests	with	no	more	than	15	cells	in	diameter;	at	least	
75%	of	papillae	and	nests	associated	or	completely	replaced	by	
psammoma	body	formation.		
	 Twenty-four	cases	of	PPSP	have	been	reported	in	the	literatu-
re	to	date	[1-13]	and	they	may	help	define	the	clinical	and	patho-
logical	features	of	this	neoplasm.	The	features	have	been	depicted	
in	Table	1.	
	 To	 sum	 up,	 an	 average	 patient	 age	 at	 clinical	 presentation	
of	 the	 disease	was	 54	 (95%	CI,	 47-61	 years).	Common	 symp-
toms	and	 signs	of	 the	disease	 included:	 abdominal	pain,	pelvic	
mass,	distension,	nausea	and	vomiting.	The	most	frequent	stage	
at	the	primary	diagnosis	was	FIGO	stage	III,	with	the	exception	
of	 the	 two	cases	described	by	Weir	 et	 al.	 [4].	The	optimal	 sur-
gical	debulking	as	 the	mainstay	was	performed	in	19	out	of	24	
described	cases.	One	patient	underwent	conservative	surgery	and	
our	patient	underwent	optimal	interval	surgery	with	primary	neo-
adjuvant	chemotherapy.	Nine	patients	were	treated	with	adjuvant	
chemotherapy	based	on	platinum	analogues,	and	one	with	pelvic	
and	abdominal	radiation	therapy.	
	 Our	patient	received	consolidation	intraperitoneal	chemothe-
rapy	with	carboplatin.	Follow-up	data	were	available	in	20	out	of	
24	cases.	
 
Figure 1. Primary peritoneal serous psammocarcinoma, 40x. Glandular cells 
minimally invade peritoneum stroma. 
 
Figure 2. Primary peritoneal serous psammocarcinoma, 400x. Histological exami-
nation revealed that neoplastic epithelium has been replaced by psammoma bodies.  
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Table I. Peritoneal serous psammocarcinoma: clinical features. 
Abbreviations: TAH – total abdominal hysterectomy, BSO – bilateral salpingo-oophorectomy, USO – unilateral salpingo-oophorectomy, 
LSO – left salpingo-oophorectomy, NA – not administered, NED – no evidence of disease, DOD – death of disease, PFS – progression free survival, 
AWD – alive with disease, i.p. – intraperitoneal, i.v. – intravenously.
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	 The	clinical	outcome	without	recurrence	of	the	disease	was	
noted	 in	 19	 out	 of	 20	 patients	 and	 the	 follow-up	 was	 from	 8	
months	to	10	years	(mean	3.6	years).	
	 These	data	suggest	a	more	favourable	event-free	survival	in	
serous	type	described	previously	by	Dubernard	et	al.	[18],	with	a	
3-year	survival	rate	(29%	in	a	group	of	37	patients).	Additionally,	
there	is	a	possibility	that	PPSP	may	have	an	aggressive	presenta-
tion,	as	described	by	Poggi	et	al.	[3]	in	their	report.	In	such	cases	
chemotherapy	appears	 to	be	of	clinical	 importance	 in	 the	 treat-
ment	of	such	an	aggressive	variant	of	PSPP.
Conclusion
	 Based	on	a	small	number	of	cases,	it	is	reasonable	to	conclu-
de	that	peritoneal	psammocarcinoma	is	a	rare	serous	tumour,	cha-
racterized	morphologically	by	invasiveness,	low-grade	cytologic	
features	 and	 abundant	 psammoma	 body	 formation.	 Prognostic	
factors	suggest	that	this	neoplasm	has	more	favourable	prognosis	
when	 comparing	 to	usual	 serous	 carcinomas.	Nevertheless,	 our	
findings	and	others	[3]	have	shown	that	PSPP	may	have	a	more	
aggressive	course	as	well.	 	 	 	 	
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